AR056217A1 - Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia - Google Patents
Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demenciaInfo
- Publication number
- AR056217A1 AR056217A1 ARP060104956A ARP060104956A AR056217A1 AR 056217 A1 AR056217 A1 AR 056217A1 AR P060104956 A ARP060104956 A AR P060104956A AR P060104956 A ARP060104956 A AR P060104956A AR 056217 A1 AR056217 A1 AR 056217A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycloalkyl
- alkyl
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable, tautomero o precursor hidrolizable in vivo de los mismos, en los cuales, G es O, NR7 o CR8R9; R1 es H, alquilo C1-6, haloalquilo C1-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2, 3, 4 o 5 R14; R2 es Q o -L-Q; o R1 y R2, junto con el átomo de carbono al cual están unidos, forman un grupo cicloalquilo de 3-14 miembros o un grupo heterocicloalquilo de 3-14 miembros, cada uno de los cuales está sustituido con Cy2 y está optativamente sustituido con 1, 2, 3, 4 o 5 A4; R3, R4, R5 y R6 son, independientemente, H, CN, NO2, ORa, SRa, OC(O)Ra, OC(O)ORb, OC(O)NRcRd, C(O)Ra, C(O)ORb, C(O)NRcRd, NRcRd, NRcC(O)Ra, NRcC(O)ORb, NRcS(O)2Rb, S(O)Ra, S(O)NRcRd, S(O)2Ra, S(O)2NRcRd, alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2 o 3 R14; R7 es H, C(O)Ra, C(O)ORb, C(O)NRcRd, S(O)Ra, S(O)2Ra, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde cada uno del alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido 1, 2, 3, 4 o 5 R14; R8 y R9 son, independientemente, H, CN, NO2, ORa, SRa, OC(O)Ra, OC(O)ORb, C(O)ORb, OC(O)NRcRd, NRcRd, NRcC(O)Ra, NRcC(O)ORb, NRcS(O)2Rb, S(O)Ra, S(O)NRcRd, S(O)2Ra, S(O)2NRcRd, alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2- 10, arilo, . cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2 o 3 R14; o R8 y R9, junto con el átomo de carbono al cual están unidos, forman un grupo cicloalquilo de 3-14 miembros o un grupo heterocicloalquilo de 3-14 miembros, cada uno de los cuales está sustituido con 1, 2 o 3 R14; cada uno de R12 y R13 es, independientemente, H, halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O)ORa', NRc'S(O)2Rb', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', o S(O)2NRc'Rd'; R14 es halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O)ORa', NRc'S(O)2Rb', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', o S(O)2NRc'Rd'; Q es arilo, cicloalquilo, heteroarilo o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con 1, 2, 3, 4 o 5 Cy1 o A1; L es alquenilenilo C2-10, alquinilenilo C2-10, (CR12R13)q, (CR12R13)q1O(CR12R13)q2, (CR12R13)q1S(CR12R13)q2, (CR12R13)q1SO2(CR12R13)q2, (CR12R13)q1SO(CR12R13)q2, (CR12R13)q1CO(CR12R13)q2, (CR12R13)q1NRe(CR12R13)q2, o (CR12R13)q1CONRe(CR12R13)q2; Cy1 es arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con 1, 2, 3, 4 o 5 A2; Cy2 es arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con 1, 2, 3, 4 o 5 A3; A1 es halo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb, S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo o heterocicloalquilalquilo, donde cada uno de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo o heterocicloalquilalquilo está optativamente sustituido con 1, 2, 3, 4 o 5 halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb', S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd; cada uno de A2, A3, y A4 es, independientemente, halo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb, S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, arilo, cicloalquilo, heteroarilo o heterocicloalquilo, donde cada uno de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, arilo, cicloalquilo, heteroarilo o heterocicloalquilo está optativamente sustituido con 1, 2, 3, 4 o 5 halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rb, S(O)Rb, S(O)NRcRd, S(O)2Rb, o S(O)2NRcRd; cada uno de Ra y Ra' es, independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquillquilo o heterocicloalquilalquilo, donde el alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, cada uno de Rb y Rb' es, independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, cada uno de Rc y Rd es, independientemente, H, alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, o Rc y Rd junto con el átomo de N al cual están unidos, forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; cada uno de Rc' y Rd' es, independientemente, H, alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, donde el alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está optativamente sustituido con OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo, o bien Rc' y Rd' junto con el átomo de N al cual están unidos, forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; Re es H, alquilo C1-4, haloalquilo C1-4, alquenilo C2-4, alquinilo C2-4, o CO-(alquilo C1-4); q es 1, 2, 3, 4, 5 o 6; q1 es 0, 1, 2 o 3; y q2 es 0, 1, 2 o 3; con las siguientes salvedades: a) cuando G es NH o CH2; R2 es -L-Q; L es -CH2, -CH=CH-, o -CsC-; y R1 es H o metilo, luego Q no ha de ser fenilo no sustituido y b) cuando G es NR7 o CR8R9; R7 es H, metilo, o fenilo optativamente sustituido con halo; cada uno de R8 y R9 es independientemente, H o metilo, R2 es Q; y R1 es H o metilo, luego Q es arilo, cicloalquilo, heteroarilo, o heterocicloalquilo, cada uno de los cuales está optativamente sustituido con por lo menos un Cy3 y está optativamente sustituido con 1, 2 o 3 A4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73732705P | 2005-11-15 | 2005-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056217A1 true AR056217A1 (es) | 2007-09-26 |
Family
ID=38049090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104956A AR056217A1 (es) | 2005-11-15 | 2006-11-13 | Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia |
Country Status (15)
Country | Link |
---|---|
US (1) | US20080293709A1 (es) |
EP (1) | EP1957462A4 (es) |
JP (1) | JP2009520685A (es) |
KR (1) | KR20080070744A (es) |
CN (1) | CN101360714A (es) |
AR (1) | AR056217A1 (es) |
AU (1) | AU2006316256A1 (es) |
BR (1) | BRPI0618607A2 (es) |
CA (1) | CA2629831A1 (es) |
IL (1) | IL191057A0 (es) |
NO (1) | NO20082481L (es) |
TW (1) | TW200804290A (es) |
UY (1) | UY29919A1 (es) |
WO (1) | WO2007058583A2 (es) |
ZA (1) | ZA200803859B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
SG162790A1 (en) | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
BRPI0612545A2 (pt) | 2005-06-14 | 2010-11-23 | Schering Corp | compostos inibidores de protease, composições farmacêuticas e uso dos mesmos |
JP5281794B2 (ja) | 2005-10-25 | 2013-09-04 | 塩野義製薬株式会社 | アミノジヒドロチアジン誘導体 |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
KR20100059919A (ko) | 2007-09-24 | 2010-06-04 | 코멘티스, 인코포레이티드 | 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물 |
US8217064B2 (en) * | 2007-12-20 | 2012-07-10 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
EP2305672B1 (en) | 2008-06-13 | 2019-03-27 | Shionogi & Co., Ltd. | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY |
EP2349308A4 (en) | 2008-10-10 | 2012-09-12 | Purdue Research Foundation | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Bace1阻害活性を有する2-アミノピリミジン-4-オンおよび2-アミノピリジン誘導体 |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
EP2376083A4 (en) | 2008-11-20 | 2012-06-20 | Purdue Research Foundation | CHINAZOLIN INHIBITORS OF BACE 1 AND METHOD OF USE |
US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
WO2011014462A1 (en) | 2009-07-27 | 2011-02-03 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
KR20120104570A (ko) | 2009-12-11 | 2012-09-21 | 시오노기세야쿠 가부시키가이샤 | 옥사진 유도체 |
JPWO2011077726A1 (ja) | 2009-12-24 | 2013-05-02 | 塩野義製薬株式会社 | 4−アミノ−1,3−チアジンまたはオキサジン誘導体 |
EP2580200B1 (en) | 2010-06-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
WO2012003392A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
EA021723B1 (ru) | 2010-09-22 | 2015-08-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 4,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-6-ИЛАМИНА, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (ВАСЕ) |
JP5766198B2 (ja) * | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
CA2816285A1 (en) * | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
MX347912B (es) | 2010-12-22 | 2017-05-17 | Janssen Pharmaceutica Nv | Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8ilaminautiles como inhibidores de beta-secretasa (bace). |
CA2824360C (en) | 2011-03-01 | 2020-01-14 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
ES2534973T3 (es) | 2011-03-09 | 2015-04-30 | Janssen Pharmaceutica N.V. | Derivados de 3,4-dihidro-pirrolo[1,2-a]pirazin-1-ilamina útiles como inhibidores de beta-secretasa (BACE) |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
JPWO2012147763A1 (ja) | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
BR112014004181A2 (pt) | 2011-08-22 | 2017-06-13 | Merck Sharp & Dohme | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia |
EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
CA2912156C (en) | 2013-06-12 | 2021-07-20 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace) |
AU2014280124B2 (en) | 2013-06-12 | 2018-11-01 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
EA028775B1 (ru) | 2013-06-12 | 2017-12-29 | Янссен Фармацевтика Нв | Производные 4-амино-6-фенил-6,7-дигидро[1,2,3]триазоло[1,5-a]пиразина в качестве ингибиторов бета-секретазы (bace) |
ES2768823T3 (es) | 2014-12-18 | 2020-06-23 | Janssen Pharmaceutica Nv | Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018616A1 (en) * | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
EP0858451A1 (en) * | 1995-10-17 | 1998-08-19 | Astra Pharmaceuticals Limited | Pharmaceutically active quinazoline compounds |
KR20000005388A (ko) * | 1996-04-13 | 2000-01-25 | 니콜라스 피터 비가르트 (니크 비가르트), 콜린 레드롭 | 아미노이소퀴놀린 및 아미노티에노피리딘 유도체 및 소염제로서의 그의 용도 |
US20030199526A1 (en) * | 2001-12-07 | 2003-10-23 | Deborah Choquette | Pyrimidine-based compounds useful as GSK-3 inhibitors |
PE20070078A1 (es) * | 2005-06-14 | 2007-03-08 | Schering Corp | Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa |
-
2006
- 2006-11-08 TW TW095141352A patent/TW200804290A/zh unknown
- 2006-11-13 KR KR1020087014418A patent/KR20080070744A/ko not_active Application Discontinuation
- 2006-11-13 EP EP06813006A patent/EP1957462A4/en not_active Withdrawn
- 2006-11-13 WO PCT/SE2006/001283 patent/WO2007058583A2/en active Application Filing
- 2006-11-13 CN CNA2006800511195A patent/CN101360714A/zh active Pending
- 2006-11-13 JP JP2008541110A patent/JP2009520685A/ja active Pending
- 2006-11-13 AU AU2006316256A patent/AU2006316256A1/en not_active Abandoned
- 2006-11-13 BR BRPI0618607-6A patent/BRPI0618607A2/pt not_active IP Right Cessation
- 2006-11-13 CA CA002629831A patent/CA2629831A1/en not_active Abandoned
- 2006-11-13 AR ARP060104956A patent/AR056217A1/es not_active Application Discontinuation
- 2006-11-13 US US12/093,631 patent/US20080293709A1/en not_active Abandoned
- 2006-11-14 UY UY29919A patent/UY29919A1/es not_active Application Discontinuation
-
2008
- 2008-04-27 IL IL191057A patent/IL191057A0/en unknown
- 2008-05-06 ZA ZA200803859A patent/ZA200803859B/xx unknown
- 2008-06-03 NO NO20082481A patent/NO20082481L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20082481L (no) | 2008-07-24 |
JP2009520685A (ja) | 2009-05-28 |
WO2007058583A3 (en) | 2007-07-05 |
KR20080070744A (ko) | 2008-07-30 |
CA2629831A1 (en) | 2007-05-24 |
AU2006316256A1 (en) | 2007-05-24 |
UY29919A1 (es) | 2007-06-29 |
WO2007058583A2 (en) | 2007-05-24 |
IL191057A0 (en) | 2008-12-29 |
ZA200803859B (en) | 2009-02-25 |
EP1957462A4 (en) | 2010-09-15 |
US20080293709A1 (en) | 2008-11-27 |
CN101360714A (zh) | 2009-02-04 |
TW200804290A (en) | 2008-01-16 |
BRPI0618607A2 (pt) | 2011-09-06 |
EP1957462A2 (en) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056217A1 (es) | Compuestos heterociclicos utiles para el tratamiento de la enfermedad de alzheimer, neurodegeneracion y demencia | |
RU2009115963A (ru) | Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами | |
RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
JP2009520685A5 (es) | ||
AR073530A1 (es) | Inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos. inserto oftalmico | |
RU2430923C2 (ru) | Тиазолилдигидрохиназолины | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
RU2016108987A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
RU2009128591A (ru) | Лиганды для визуализации иннервации сердца | |
RU2006122209A (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
IL298983B1 (en) | Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
ES2561507T3 (es) | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus | |
HRP20130918T1 (hr) | Derivati 4-aminopirimidina kao receptori antagonista histamina h4 | |
AR045955A1 (es) | Compuestos benzoimidazolicos | |
AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
NO20081056L (no) | Nye, heterosykliske NF-kB-inhibitorer | |
RU2012116526A (ru) | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы | |
RU2014122335A (ru) | ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |